# Macera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/macera-therapeutics

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Latest round: Angel (Dec 8, 2022)
- Investors on record: 3

## About

Based in Nanjing, China, and established in 2022, Nanjing Yuanmai Cell Biotechnology Co., Ltd., dba Macera Therapeutics, is a biotechnology company engaged in the R&D of macrophage cell immunotherapy new drugs for tumors. The company was co-founded by Pingping Shen, a Professor at the School of Life Sciences, Nanjing University and Yijun Chen who holds a PhD from the National University of Singapore School of Medicine and worked at Singapore General Hospital conducting research in tumor endocrinology.

In May 2026, Macera Therapeutics closed a round of venture funding from Fanchuang Capital and Dingxin Capital.

Macera Therapeutics engages in the R&D of new drugs for treating fibrotic diseases and solid tumors adopting the CAR-Macrophage technology. It also developed molecular editing and manipulation systems, IPSC-derived immune cell differentiation systems, ligand-receptor, and other information flow recognition and conduction technology platforms, which can edit the genes, identify the target antigens, and kill the tumor cells. 

The company generates revenue from developing macrophage immunotherapy drugs for the treatment of solid tumors and autoimmune diseases.

## Funding rounds

- Angel, Dec 8, 2022 — CDH Investments, Nanjing Jiangbei New Area Sci-Tech Investment Group, Tianjin Renai Group

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Angel
- Nanjing Jiangbei New Area Sci-Tech Investment Group — Angel
- Tianjin Renai Group — Angel